MOTS-c Peptide Dosage: A Physician's Protocol Guide

At a Glance

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) sits in a category apart from most peptides I prescribe. Unlike synthetic analogues of growth factors or modified fragments of naturally occurring proteins, MOTS-c is encoded directly in mitochondrial DNA — specifically in the 12S ribosomal RNA gene. It is one of a handful of mitochondria-derived peptides (MDPs) that communicate between the mitochondria and the rest of the cell, acting almost as a real-time readout of metabolic state.

What makes this clinically interesting is its mechanism. MOTS-c activates AMPK (AMP-activated protein kinase) — the same energy-sensing enzyme activated by exercise, caloric restriction, and metformin. But it does so through a distinct route involving the one-carbon metabolic pathway and AICAR, a purine biosynthesis intermediate that functions as a natural AMPK agonist. The result is a coordinated metabolic shift: improved glucose uptake, enhanced fatty acid oxidation, and suppression of de novo lipogenesis.

In patients presenting with metabolic inflexibility, early insulin resistance, or physical decline disproportionate to their age, MOTS-c has become one of my most-used tools. This guide covers how I dose it, how I cycle it, and how I decide who gets it.

How MOTS-c Works: The Mitochondrial Signal You’re Amplifying

Before discussing dose, it’s worth understanding what you’re amplifying. Under physiological stress — caloric restriction, exercise, hypoxia, heat — mitochondria upregulate MOTS-c production. The peptide translocates to the nucleus, where it modulates gene expression, then enters systemic circulation to act on peripheral tissues.

Its two best-documented effects are:

1. Insulin sensitisation in skeletal muscle and adipose tissue — MOTS-c promotes GLUT4 translocation and glucose transporter expression independent of insulin signalling, making it additive (not redundant) with insulin itself.
2. Exercise mimicry — It recapitulates several transcriptional and metabolic adaptations of endurance exercise, including mitochondrial biogenesis signals and suppression of reactive oxygen species at Complex I.

A 2021 Nature Communications paper by Reynolds et al. demonstrated that exogenous MOTS-c injections partially reversed age-related physical decline in aged mice, improving exercise capacity and muscle homeostasis even in sedentary animals. In human cohort studies, naturally higher circulating MOTS-c has been observed in centenarians and elite endurance athletes, supporting the hypothesis that this peptide is a longevity-associated signal rather than a mere acute metabolic regulator.

This translational picture shapes my clinical approach: MOTS-c is most powerful in patients who are already exercising, not as a substitute for physical activity.

Standard Dosage Protocols

Starting Protocol (Weeks 1–2)

I begin all patients at 5 mg subcutaneously, three times per week (e.g., Monday / Wednesday / Friday), administered 30–60 minutes before the morning training session. This dose is sufficient to produce measurable AMPK activation while allowing us to assess individual response before increasing.

At 5 mg, most patients notice:

• Improved exercise-session energy within the first 1–2 weeks
• Mild reduction in post-meal glucose variability (captured on CGM if worn)
• Occasional transient warmth or mild flushing at the injection site — a self-limiting vasodilatory response

If the 5 mg dose is well-tolerated and the patient’s goals include stronger metabolic or anti-ageing effects, I advance to the maintenance range after two weeks.

Maintenance Protocol (Weeks 3–8)

The standard maintenance range is 5–10 mg, three to five times per week. The majority of my patients stabilise at 10 mg × 4 times per week. Injection timing remains pre-exercise when possible, though a fixed morning window (within 60 minutes of waking) is an acceptable alternative for non-exercising days.

For metabolic syndrome and insulin resistance as primary indications, I tend toward the upper end: 10 mg × 5 days per week, alongside lifestyle measures. CGM and fasting insulin are re-checked at week 6.

For longevity and anti-ageing as primary goals in otherwise healthy patients, 5–10 mg × 3 times per week is appropriate and reduces cumulative peptide burden.

Advanced Dosing (Research Context)

Some clinical protocols and published human research have extended to 15 mg per injection, primarily in subjects with significant insulin resistance or metabolic dysfunction. I reserve this range for patients in whom lower doses have produced a plateau in response and the indication remains compelling. The dose-response relationship above 10 mg is less linear, and I do not routinely push higher without CGM and metabolic panel confirmation of ongoing benefit.

Injection Technique and Reconstitution

MOTS-c arrives as a lyophilised powder (typically in 5 mg or 10 mg vials). Reconstitute with bacteriostatic water — not sterile water, as bacteriostatic water allows multi-dose use over 28 days. I recommend adding the water slowly by injecting it down the side of the vial to avoid disturbing the lyophilised cake; never shake — swirl gently until the peptide dissolves.

Injection sites: Subcutaneous injection into the abdomen (lateral to the umbilicus), outer thigh, or lateral upper arm. Rotate sites with each injection to prevent localised lipoatrophy.

Storage: Lyophilised vials at room temperature or refrigerated. Reconstituted solution must be stored at 2–8 °C and used within 28 days. Do not freeze reconstituted peptide.

Needle gauge: 29–31 G, 8–13 mm insulin needle. Draw up with an 18 G needle to speed preparation, then swap to the injection needle.

Cycling Strategy

Like most peptides operating through receptor-mediated or pathway-mediated mechanisms, MOTS-c benefits from structured cycling to maintain receptor sensitivity and avoid tachyphylaxis of AMPK signalling pathways.

Standard cycle: 4–6 weeks on, 2–4 weeks off for most patients.

Extended cycle (longevity protocols): Some integrative longevity practitioners use an 8-week on / 4-week off cycle, particularly when MOTS-c is combined with NAD+ precursors and other mitochondrial support. I have not observed tolerance issues at this duration, but systematic data are absent.

Seasonal approach: Given MOTS-c’s parallels with exercise adaptation signals, I have found that cycling it during high-volume training blocks (endurance athletes in base-building phase, for example) yields the most patient-reported benefit, with off-cycles during de-load or travel periods.

During off-cycles, maintaining AMPK pathway activity through consistent aerobic exercise, time-restricted eating, and berberine or metformin (where indicated) preserves the baseline improvements achieved.

Who Benefits Most: Patient Selection

Strongest candidates:

• Metabolic syndrome with fasting insulin > 15 μIU/mL or HOMA-IR > 2.5
• Pre-diabetes (HbA1c 5.7–6.4%) with impaired glucose response on CGM
• Healthy-aging patients with age-related physical decline (VO2max decline, grip strength reduction)
• Athletes seeking improved metabolic efficiency without prohibited substances (MOTS-c is not on the WADA prohibited list as of 2026)
• Post-COVID patients with documented mitochondrial dysfunction (elevated lactate, low exercise tolerance out of proportion to cardiac/pulmonary findings)

Moderate candidates:

• Patients with elevated inflammatory biomarkers (CRP, IL-6) and metabolic inflexibility
• Women with PCOS and insulin resistance as the primary driver
• Patients on GLP-1 agonists who want to preserve or build muscle mass alongside fat loss

Poor candidates / caution required:

• Active or recently treated malignancy (theoretical AMPK activation concerns; MOTS-c’s direct proliferative effect in cancer cells is not established, but I apply precautionary logic)
• Pregnancy and breastfeeding (no safety data)
• Patients with severe hepatic impairment (MOTS-c is renally and hepatically cleared; dosage adjustments are theoretical — no clinical guidance exists)

Stacking MOTS-c with Other Therapies

MOTS-c is frequently most effective within a broader mitochondrial support protocol. The combinations I use most:

MOTS-c + NAD+ IV: Synergistic at the mitochondrial level. NAD+ replenishment enhances the electron transport chain efficiency that MOTS-c’s AMPK activation depends upon. I typically run NAD+ IV infusions on MOTS-c injection days during induction.

MOTS-c + Epithalon: For pure longevity-focused patients, this pairing addresses both mitochondrial metabolic function (MOTS-c) and telomere maintenance / pineal peptide axis (Epithalon). Epithalon is dosed separately on non-MOTS-c days to simplify the injection schedule.

MOTS-c + BPC-157: Relevant for patients with musculoskeletal pathology alongside metabolic goals. BPC-157’s angiogenic and tissue-repair mechanisms are complementary rather than overlapping with MOTS-c’s metabolic-axis actions.

MOTS-c + Berberine or Metformin: AMPK-pathway stacking. In patients where cost or access limits peptide use, berberine (500 mg TID) maintains AMPK tone during off-cycles. If the patient is already on metformin, I do not find MOTS-c to cause problematic redundancy — the mechanisms partially overlap but the magnitude of benefit appears additive in clinical observation.

Monitoring and Endpoints

Before starting MOTS-c and at the end of each cycle, I track:

• Fasting glucose, insulin, HOMA-IR — primary metabolic endpoints
• HbA1c (if relevant to indication)
• Fasting lipids — MOTS-c tends to reduce triglycerides in metabolically dysregulated patients
• CGM trace (2-week wear) — captures post-prandial variability that fasting labs miss
• VO2max or 6-minute walk test — for physical-decline indication
• DEXA or BIA — lean mass and fat mass if body composition is a goal

Patient-reported outcomes that signal positive response include improved exercise session quality, reduced post-meal energy crash, better sleep quality (likely secondary to improved metabolic stability), and a subjective sense of physical resilience.

Related Articles

• MOTS-c: Mitochondrial Peptide Overview — What MOTS-c is, how it was discovered, and its biological significance
• Mitochondria and Longevity: Why Mitochondrial Health Is the Engine of Aging — The foundational science behind why mitochondrial peptides matter
• Epithalon Dosage Guide — Protocol comparison for another leading longevity peptide
• NAD+ IV Therapy: What to Expect — How NAD+ infusions complement MOTS-c’s mitochondrial effects
• Peptide Stacking Guide — How to combine multiple peptides safely and effectively

References

1. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PMID: 25738459
2. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33469043
3. Ming W, et al. Exogenous MOTS-c peptide ameliorates insulin resistance in high-fat diet-induced mice. Mol Cell Endocrinol. 2021;522:111126. PMID: 33333128
4. Zempo H, et al. A mitochondrial-derived peptide MOTS-c affects steroidogenesis in mouse adrenal cells. Endocr J. 2021;68(12):1429–1433. PMID: 34248091
5. Kim SJ, et al. MOTS-c: Mitochondrial signaling under metabolic and environmental stress in aging and age-related diseases. Oxid Med Cell Longev. 2021;2021:5597322. PMID: 34221225
6. Fuku N, et al. The mitochondrial-derived peptide MOTS-c: A player in exceptional longevity? Ageing Res Rev. 2015;27:16–18. PMID: 26556616
7. Kumagai H, et al. Mitochondria-derived peptides, humanin and MOTS-c: A novel linkage of mitochondria to physiological regulation and disease. Br J Pharmacol. 2022;179(4):721–741. PMID: 34155632